Bicycle Therapeutics (BCYC) Non-Current Deferred Tax Liability (2022 - 2023)
Bicycle Therapeutics (BCYC) posted Non-Current Deferred Tax Liability of $3.4 million for Q4 2023, down 23.1% on a QoQ basis from $4.4 million in Q4 2022, and down 23.1% year-over-year from $4.4 million in Q4 2022.
Bicycle Therapeutics (BCYC) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
Bicycle Therapeutics' Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $3.4 million for Q4 2023.
- Quarterly Non-Current Deferred Tax Liability fell 23.1% year-over-year to $3.4 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $3.4 million (down 23.1% YoY) and the FY2023 annual result came in at $3.4 million, down 23.1% from the prior year.
- Non-Current Deferred Tax Liability was $3.4 million for Q4 2023 at Bicycle Therapeutics, down from $4.4 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $4.4 million in Q4 2022 and bottomed at $3.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Bicycle Therapeutics | 289.88 Mn | 289.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 3.39 Mn |
| Dec 31, 2023 | 3.39 Mn |
| Dec 31, 2022 | 4.41 Mn |
| Dec 31, 2022 | 4.41 Mn |